Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993142 | 0.96 | ALDH1A1 (0.44) | GAAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1739339 | 0.95 | ALDH1A1 (0.46) | GAAALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL24512542 | 0.95 | ALDH1A1 (0.46) | GAAALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL1694342 | 0.92 | GAA (0.44) | GAAALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL27006521 | 0.84 | GAA (0.42) | GAAALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL15566866 | 0.84 | ALDH1A1 (0.40) | GAAALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL27130827 | 0.84 | GAA (0.42) | GAAALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL15005911 | 0.82 | HPGD (0.34) | GAASMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL28548543 | 0.82 | GAA (0.37) | GAAALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL28548541 | 0.82 | GAA (0.37) | GAAALDH1A1SMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9605007-B2 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | PFIZER INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-9428523-B2 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | PFIZER INC. (US) | 2016-08-30 | — | — | US | claimed |
| US-20160152637-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2016-06-02 | — | — | US | claimed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4605397-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-120035594-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-118434737-A | Aromatic heterobicyclic compounds and antiviral uses thereof | 苏州爱科百发生物医药技术有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024086634-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-116425754-A | Aromatic heterobicyclic compounds and antiviral uses thereof | 苏州爱科百发生物医药技术有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20170008911-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9428523-B2 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | PFIZER INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160152637-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9315520-B2 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | PFIZER INC. (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2015155626-A1 | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | PFIZER INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291621-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2010043633-A1 | 2H-PYRAZOLO [4,3-D]PYRIMIDIN-5-AMINE DERIVATIVES AS H4 HISTAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGIC, IMMUNOLOGICAL AND INFLAMMATORY DISEASES | PALAU PHARMA, S. A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | GAA 822/4885ALDH1A1 118/4885SMN1; SMN2 3076/4885 |
| US-20160152637-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | TPMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8 | GAA 2196/4885ALDH1A1 198/4885SMN1; SMN2 622/4885 |
| US-20170008911-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | TPMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8 | GAA 2196/4885ALDH1A1 198/4885SMN1; SMN2 622/4885 |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | GAA 986/4885ALDH1A1 1313/4885SMN1; SMN2 2233/4885 |
| US-20150291621-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | TPMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8 | GAA 2196/4885ALDH1A1 198/4885SMN1; SMN2 622/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | GAA 986/4885ALDH1A1 1313/4885SMN1; SMN2 2233/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | GAA 572/4885ALDH1A1 474/4885SMN1; SMN2 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.